Skip to main content
Clinical Trials/NCT05935800
NCT05935800
Active, not recruiting
Not Applicable

The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates

Methodist Health System1 site in 1 country208 target enrollmentApril 19, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Frailty
Sponsor
Methodist Health System
Enrollment
208
Locations
1
Primary Endpoint
To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures [1]. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.

Detailed Description

This study seeks to examine whether the SARS-CoV-2 (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.

Registry
clinicaltrials.gov
Start Date
April 19, 2022
End Date
April 19, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC

Exclusion Criteria

  • Not a patient at Liver Institute at Methodist Dallas

Outcomes

Primary Outcomes

To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia

Time Frame: 2 years

To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center

To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia

Time Frame: 2 years

To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center

Secondary Outcomes

  • Changes in number of comorbidities between pre- and during/post-pandemic periods(1 year)
  • Changes in severity of comorbidities between pre- and during/post-pandemic periods(1 year)
  • Changes in type of comorbidities between pre- and during/post-pandemic periods(1 year)

Study Sites (1)

Loading locations...

Similar Trials